Asymmetrex’s latest research report verifying the presence of immortal DNA strands in human tissue stem cells was featured by Kerafast. While other reports have verified immortal DNA strands in stem cells in species such as mold, plants, insects and mice, Asymmetrex’s new study is the first to describe the occurrence of immortal DNA strands in
Superb Crew interviewed Asymmetrex Director James Sherley to discuss the latest Asymmetrex report of a new advance on stem cell immortality. This interview goes into detail about how stem cell immortality is connected with kinetic stem cell counting, how it will impact the future of kinetic stem cell counting technology, and Asymmetrex’s connection to this
Asymmetrex has partnered with Proventa International to provide an online workshop on kinetic tissue stem cell counting for better medicine through counting stem cells to improve regenerative and pharmaceutical medicines. The online workshop is on February 18, 2021 at 11AM PST / 2PM EST. In 2020, the FDA’s Standards Coordinating Body (SCB) identified specific counting
Read Asymmtrex’s latest article in RegMedNet to learn more about its newest technologies, the TORTOISE TestTM and RABBIT CountTM, for analytical and rapid stem cell counting through computing. The TORTOISE TestTM is a tool for tissue stem cell-specific kinetics analyses, and the RABBIT CountTM is a tool for routine rapid tissue stem cell counting. Learn more
Asymmetrex recently wrote a report, A Computational Simulation Technology for Specific Counting of Perinatal and Postnatal Human Tissue Stem Cells for Transplantation Medicine, that was published as the cover story in OBM Transplantation Special Issue: Isolation and Characterization of Adult Therapeutic Cells. Read this detailed report to learn more about how the integration of principles
On September 30, stem cell biotechnology company Asymmetrex presented at the 2020 Outsourcing in Clinical Trials USA Virtual Conference. In addition to discussing the value of tissue stem cell counting for better practices in stem cell and gene therapy clinical trials, Asymmetrex director James Sherley also highlighted value that stem cell counting technologies can impart
Asymmetrex recently received a $0.42 million award from the NIH-National, Heart, Lung, and Blood Institute to support technical development and commercialization of its first-in-kind technology for specific and accurate counting of therapeutic tissue stem cells. Tech Company News reached out to Asymmetrex Director James L. Sherley to interview him about this achievement and how the
On September 19, 2020, stem cell biotechnology company Asymmetrex was awarded a research and development grant from the NIH-NHLBI. The $0.42 million grant was awarded to support the company’s technical development and commercialization of its first-in-kind technology for specific and accurate counting of therapeutic tissue stem cells. On the heals of Asymmetrex’s recently published peer-reviewed report describing its development
In a recent report published in the journal OBM Transplantation, stem cell biotechnology company Asymmetrex reported the first counts of therapeutic “true” tissue stem cells in the history of stem cell science and medicine. This crucial research and clinical data, long-needed for accelerating the development of new and better stem cell medicines, is now readily
In an August 28 special issue of the peer-reviewed online journal OBM Transplantation, stem cell biotechnology company Asymmetrex has now published a report describing how its technology for determining the specific dosage of therapeutic tissue stem cells works. The new technology is poised to revolutionize stem cell science and stem cell medicine by giving the